Biopharmaceutical Company Submits SMA-Targeted Apitegromab for FDA Biologics License Scholar Rock, a Cambridge, Massachusetts-based late-stage biopharmaceutical company, has submitted a Biologics License Application to the U.S. Food & Drug Administration (FDA) for apitegromab, described as “a muscle-targeted therapy designed and developed to provide clinically meaningful improvement in motor function for people living with SMA [spinal…